When the drugs don't work: the potential of glutamatergic antipsychotics in schizophrenia.
نویسندگان
چکیده
Currently available antipsychotic drugs target dopaminergic neurotransmission. Many patients do not respond fully to these treatments, and there has been considerable effort to investigate alternative targets. Here we summarise the rationale and recent evidence supporting efforts to develop glutamatergic antipsychotic drugs.
منابع مشابه
مقایسه تاثیر ریسپریدون و هالوپریدول بر نشانه های شناختی اسکیزوفرنیا
Background and purpose: Several studies have demonstrated, that atypical antipsychotics attenuate cognitive symptoms of schizophrenia more than first generation of antipsychotics. Because there was no comprehensive and reliable study on evaluating these effects in Iranian population, the research group decided to compare the effects of haloperidol and risperidone, both Iranian drug laboratori...
متن کاملEffect of Memantine on Positive Sign in Patients with Schizophrenia and Schizoaffective Disorders: A Randomized Double Blind Placebo Controlled Trial
Background and purpose: Memantine is a medication used to treat moderate to severe Alzheimer’s disease. Memantine targeting the glutamatergic system specifically N-Methyl-D-Aspartate offer a novel approach in treatment of psychiatric disorders such as schizophrenia and schizoaffective disorder. The purpose of this study was to evaluate the efficacy and safety of memantine in combination with an...
متن کاملBeyond Dopamine: Glutamate as a Target for Future Antipsychotics
The dopamine hypothesis of schizophrenia remains the primary theoretical framework for the pharmacological treatment of the disorder. Despite various lines of evidence of dopaminergic abnormalities and reasonable efficacy of current antipsychotic medication, a significant proportion of patients show suboptimal treatment responses, poor tolerability, and a subsequent lack of treatment concordanc...
متن کاملEvaluation of the efficacy and safety of pregabalin as an adjuvant to antipsychotics in patients with chronic schizophrenia: a six-week pilot double-blind placebo-controlled trial
Introduction and objectives: Antipsychotics or dopamine receptor antagonists are the major components of treatment but about 10-20% of patients with schizophrenia do not benefit from treatment with antidopaminergic agents, indicating other neuronal systems may be involved in this disorder (2). Dysregulation of both excitatory and inhibitory mechanisms N-Methyl-D-aspartic acid (NMDA) and γ-Amino...
متن کاملمقایسه مصرف آنتی‌سایکوتیک‌های تیپیک و آتیپیک در ایجاد علایم وسواسی بیماران مبتلا به اسکیزوفرنیا
AbstractObjectives: The effects of typical and atypical antipsychotics on inducing obsessive-compulsive symptoms in patients with schizophrenia were compared in this study. Method: In a comparative-descriptive study 64 patients with schizophrenia (32 patients in typical antipsychotic group and 32 patients in atypical antipsychotic group) were investigated. All patients with a confirmed diagnosi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The British journal of psychiatry : the journal of mental science
دوره 202 شماره
صفحات -
تاریخ انتشار 2013